Gilead CEO, CFO, and Sales Head Sell Thousands of Shares in Planned Transaction

At Gilead Sciences, Inc. (NASDAQ: GILD), on May 15 Johanna Mercier, Chief Commercial and Corporate Affairs Officer, exercised 25,000 unexercised stock options at $66.64 per share. Under her 10b5-1 trading plan executed the same day, she sold tens of thousands of common shares in the open market, generating approximately $3.5 million to $3.6 million (about KRW 5 billion). Her holdings declined to roughly 125,000 shares.

That same day, Chief Financial Officer Andrew D. Dickinson sold 3,000 common shares at an average price of $132.27 per share under his 10b5-1 plan, raising about $390,000 (roughly KRW 500 million) and reducing his stake to around 173,000 shares.

On June 1, Chairman and CEO Daniel O’Day, also pursuant to a 10b5-1 trading plan, sold a total of 15,000 shares in multiple transactions at prices between $131 and $133 per share on the open market. He realized about $2 million (around KRW 2.7 billion), and his direct holding modestly decreased to approximately 617,000 shares.

Recently, Gilead, in partnership with Merck, announced positive topline results from the Phase 3 ISLEND-1 and ISLEND-2 trials of their once-weekly oral HIV treatment candidate combining islatravir and lenacapavir. Both studies met the 48-week primary endpoints, bolstering expectations for long-term growth in Gilead’s HIV portfolio.

In the first quarter of 2026, the company reported revenues that exceeded analysts’ estimates and raised its full-year revenue guidance. However, acquisition-related charges prompted a modest downward revision of its annual earnings forecast.

Headquartered in Foster City, California, Gilead is a leading biopharmaceutical company specializing in antiviral therapies for HIV and hepatitis, as well as oncology and cell therapy treatments.